重组促红细胞生成素防治支气管肺发育不良的临床研究

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (315 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨重组促红细胞生成素(rhEpo)防治支气管肺发育不良(BPD)的效果。方法选择胎龄<32周、需机械通气(包括常频及高频)治疗的患儿103例,随机分为促红细胞生成素组(51例)和常规治疗组(52例),比较两组在生后28 d BPD发生率、纠正胎龄36周时BPD严重程度、死亡率、住院时间、呼吸机治疗时间、氧疗时间和并发症的发生率。结果促红细胞生成素组和常规治疗组BPD发生率(11.8%和28.8%)、纠正胎龄36周时BPD严重程度、住院时间[(32.6±11.2)d和(44.3±9.7)d]、输血量[(28.6±12.7)ml/kg和(39.6±10.6)ml/kg]和贫血发生率(35.3%和61.5%)比较,差异均有统计学意义。结论 rhEpo治疗有BPD风险的早产儿可减少BPD的发生率及减轻BPD程度,减少氧疗时间,缩短住院时间,未增加早产儿视网膜病(ROP)的发生率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	刘丽芳
	许茜
	蔡琳
	李晓东
	何中倩
	陈宏洁

关键词 ：早产儿, 支气管肺发育不良, 重组促红细胞生成素, 预防, 呼吸衰竭

Abstract：Objective To examine the effect of recombinant erythropoietin (rhEpo) in the treatment of bronchial pulmonary dysplasia (BPD).Methods 103 newborns with gestational age <32 weeks and requiring mechanical ventilation (including the frequency and high frequency) were randomly divided into erythropoietin (51 cases) group or routine treatment group (52 cases). Incidence of BPD at 28th day after birth, 36th week BPD severity adjusted for gestational age, mortality, length of hospital stay, ventilator treatment time, oxygen therapy, and incidence of complications were compared between the two groups.Results Incidence of BPD adjusted for gestational age at 36th week (11.8% vs. 28.8%), mortality (9.8% vs.13.5%), length of hospital stay [(32.6±11.2)d vs. (44.3±9.7)d], blood transfusion volume [(28.6±12.7) ml/kg vs. (39.6±10.6) ml/kg), and incidence of anemia (35.3% vs. 61.5%) were statistically significant between the two groups.Conclusion Treatment with rhEpo can reduce the incidence of BPD, level of BPD, duration of oxygen use and hospitalization days, while no increase in retinopathy in preterm newborns.

Key words： Prematurity Bronchopulmonary dysplasia Recombinant erythropoietin Respiratory failure

收稿日期: 2013-12-31

引用本文:

刘丽芳, 许茜, 蔡琳, 李晓东, 何中倩, 陈宏洁. 重组促红细胞生成素防治支气管肺发育不良的临床研究[J]. 中国生育健康杂志, 2014, 25(6): 528-530.
LIU Lifang, XU Xi, CAI Lin, LI Xiaodong, HE Zhongqian, CHEN Hongjie. Treatment with recombinant erythropoietin for bronchopulmonary dysplasia. Chinese Journal of Reproductive Health, 2014, 25(6): 528-530.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2014/V25/I6/528

1 Kugelman A,Durand M.A comprehensive approach to the prevention of bronchopulmonary dysplasia.Pediatr Pulmonol,2011,46:1153-1165.
2 邵肖梅,叶鸿瑁,丘小汕,主编.实用新生儿学.第4版.北京:人民卫生出版社,2011:416-417.
3 潘睿,常立文,李文斌.支气管肺发育不良与遗传因素的相关分析.实用儿科临床杂志,2012,27:1230-1232.
4 丁璐,吴本清,黄进洁,等.重组人促红细胞生成素对新生大鼠高体积分数氧肺损伤的防治效果.实用儿科临床杂志,2009,24:431-433.
5 丁璐,吴本清,黄进洁,等.促红细胞生成素对新生大鼠高氧肺损伤细胞凋亡的影响.中国当代儿科杂志,2010,12:576-579.
6 王晓蕾,薛辛东.促红细胞生成素对高氧肺损伤炎症反应病理过程的影响.中华儿科杂志,2009,47:446-451.
7 王晓蕾,岳冬梅,陈宁,等.促红细胞生成素对高体积分数氧肺损伤大鼠单核细胞趋化蛋白-1表达的影响.实用儿科临床杂志,2010,25:92-95.
8 Kakavas S,Demestiha T,Vasileiou P,et al.Erythropoetin as a novel agent with pleiotropic effects against acute lung injury.Eur J Clin Pharmacol,2011,67:1-9.
9 Ozer EA,Kumral A,Ozer E,et al.Effects of erythropoietin on hyperoxic lung injury in neonatalrats.Pediatr Res,2005,58:38-41.
10 Mailaparambil B,Krueger M,Heizmann U,et al.Genetic and epidemiological risk factors in the development of bronchopulmonary dysplasia.Dis Markers,2010,29:1-9.
11 Lavoie PM,Dubé MP.Genetics of bronchopulmonary dysplasia in the age of genomics.Curr Opin Pediatr,2010,22:134-138.
12 Ashley RA,Dubuque SH,Dvorak B ,et al.Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells.Pediatr Res,2002,51:472-478.
13 Watanabe D ,Suzuma K,Matsui S,et al.Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy.N Engl J Med,2005,353:782-792.
14 Marti HH.Erythropoietin and the hypoxic brain.J Exp Biol,2004,207:3233-3242.
15 Rayjada N, Barton L, Chan LS, et al.Decrease in incidence of bronchopulmonary dysplasia with erythropoietin administration in preterm infants:a retrospective study.Neonatology, 2012,102:287-92.